Chasing the Unexpected (Nyla)

Chapter 349

“In the past year, our team has worked tirelessly, delving deep into the mechanisms of cancer and exploring new treatment strategies. Today, I am proud to announce that we’ve developed a ‘Long–acting Drug“,” Brendan said, his voice brimming with pride.

“This ‘Long–acting Drug‘ not only exhibits a high level of specificity, precisely targeting cancer cells, but it also maintains therapeutic effects in the body for an extended period. This means cancer patients can expect longer survival times and an improved quality of life.”

Brendan’s announcement was met with enthusiastic applause and

cheers from the audience.

As Brendan finished his speech, other researchers began presenting their findings.

Caroline was the fifth speaker. Dressed in a simple white lab coat with her hair neatly tied back, she projected a professional and capable image.

She started by displaying a series of detailed experimental data charts.

Pointing to the data on the screen, she explained, “These are the results of the in vitro and in vivo experiments we’ve conducted over the past few months on the ‘Long–acting Drug‘.

we can

inhibiting the growth and spread of cancer

and

Chapter 340

+25 BONUS

and no major side effects. have been observed. This further confirms the drug’s safety and efficacy. However, it will still be some time before this

presentation generated great interest among the audience, with many people eager to learn more

acting Drug“.

patiently answered each

discussions about the “Long–acting Drug” became increasingly intense. Even after

figures from Saintornia were also in attendance. Drug development required significant funding, and potential sponsors could greatly alleviate the financial burden

research.

a smile and asked, “Nyla,

shook her head and answered seriously, “Not at

she hadn’t abandoned her recommendation to stay in academia and returned to Saintornia, she might have

quickly dismissed that